About GoodGut
GoodGut is a Healthcare company based in Girona (Spain) founded in 2014, and was acquired by HIPRA in September 2021. Diagnosis and treatment of digestive diseases based on intestinal microbiota analysis. GoodGut has raised $900.24 thousand across 2 funding rounds from investors including HIPRA and Business Angels Girona. GoodGut offers products and services including TestUrGut, RAID-Dx, RAID-Monitor, RAID-CRC, and RAID-Prediction. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
GoodGut is focussed on diagnosis and treatment of digestive diseases based on a know -how that conceives the intestinal microbiota as a determinant factor for digestive diseases development. GoodGut is a spin-off initiative of the University of Girona (UdG) and the Biomedical Research Institute of Girona. The main GoodGut objective is to offer technological instruments for a faster, more reliable and cost-effective digestive diseases diagnosis than the existing methods. At the same time, GoodGut wants to provide therapy for improving the life quality of patients with delicated digestive health. They are currently developing RAID-CRC (an automated stool-based assay to detect microbiological markers), a prediagnostic test for colorectal cancer, and PREVIPECT, a prebiotic for irritable bowel syndrome.
Products & Services of GoodGut
GoodGut offers a comprehensive portfolio of products and services, including TestUrGut, RAID-Dx, RAID-Monitor, RAID-CRC, and RAID-Prediction.
Assesses microbiota status to diagnose and improve intestinal health.
Diagnoses irritable bowel syndrome through microbiota evaluation.
Monitors inflammatory bowel diseases for better disease management.
Evaluates risk of colorectal cancer via microbiota analysis.
Predicts digestive disease progression using advanced testing.
Supports digestive health as a supplementary treatment option.
Funding Insights of GoodGut
GoodGut has successfully raised a total of $900.24K across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $667.55 thousand completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $900,240
- Total Rounds 2
- Last Round Angel Round — $667,550
- First Round $232,690
(Oct 2014)
- Investors Count 1
All 2 funding rounds of GoodGut with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $667,550 | Angel Round | – | – | |
| Oct 2014 | $232,690 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in GoodGut
GoodGut has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include HIPRA and Business Angels Girona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A non-profit network of angel investors in Girona is operated. | bagi.cat | Girona, Spain | ||
Vaccines and diagnostic kits for animal diseases are developed. | 1996 | hipra.com | Amer, Spain |
Investor details for GoodGut
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GoodGut
1 people are tracked at GoodGut (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mariona Serra-Pagès | CEO | Leadership |
Complete people profiles for GoodGut
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GoodGut
4 dated milestones of GoodGut across 7 years, from founding to its latest funding, stage changes and deals.
- Founded GoodGut is founded.
- Funding First funding round of $233K.
- Funding Latest funding round, Angel Round, of $668K.
- Exit Acquired by HIPRA.
Web traffic of GoodGut
The website of GoodGut (goodgut.eu) receives about 3.3K visits a month.
- Monthly visits3.3K
▲ 48% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Goodgut
Complete news archive for GoodGut
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GoodGut
GoodGut was founded in 2014.
GoodGut is headquartered in Girona, Spain. It is registered at Girona, Cataluna, Spain.
GoodGut is a funded company, having raised a total of $900.24K across 2 funding rounds to date. The company's 1st funding round was a Seed of $232.69K, raised on Oct 2014.
GoodGut is focussed on diagnosis and treatment of digestive diseases based on a know -how that conceives the intestinal microbiota as a determinant factor for digestive diseases development. GoodGut is a spin-off initiative of the University of Girona (UdG) and the Biomedical Research Institute of Girona. The main GoodGut objective is to offer technological instruments for a faster, more reliable and cost-effective digestive diseases diagnosis than the existing methods. At the same time, GoodGut wants to provide therapy for improving the life quality of patients with delicated digestive health. They are currently developing RAID-CRC (an automated stool-based assay to detect microbiological markers), a prediagnostic test for colorectal cancer, and PREVIPECT, a prebiotic for irritable bowel syndrome.
GoodGut offers TestUrGut, RAID-Dx, RAID-Monitor, RAID-CRC, and 2 more products and services.
GoodGut has 2 investors. Key investors include HIPRA, and Business Angels Girona.
Yes. GoodGut was acquired by HIPRA in September 2021.